Announcements

14.12.2018

Swissmedic laboratory publishes test method for nitrosamines in sartans

Test method for active substances and finished medicinal products

13.12.2018

ICH Meeting in Charlotte, USA, 10–15 November 2018

Continuation of harmonisation efforts in an increasingly global International Council for Harmonisation

04.12.2018

Reclassification of medicinal products from dispensing category D to E: evaluation concluded

More medicines available for sale over the counter – Patient safety paramount

29.11.2018

Verkaufsabgabe 2018 – Selbstdeklaration

Eingabefrist: 25. Januar 2019

23.11.2018

Analysis of the valsartan batches recalled in July 2018 confirms NDMA contamination

Presence of impurities in recalled valsartan products now proven

16.11.2018

Reclassification of therapeutic products in dispensing category C: Evaluation concluded

The prevailing supply category C will be eliminated.

14.11.2018

Renewed discovery of impurities in valsartan-containing medicines

Swissmedic laboratory discovers contamination with N-nitrosodiethylamine above the tolerated level in certain valsartan batches

06.11.2018

Swissmedic Vigilance News Edition 21

Keywords in this edition: Isotretinoin, DOAC, confusions amphotericin B formulations, guest articles RPVC, transfusion practice, statistical review 2017

05.11.2018

Valsartan: Proprietary medicines on the Swiss market containing sartans are safe in respect of NDMA

Analytical results to date for the proprietary medicinal products containing the active substances valsartan, losartan, olmesartan, candesartan and irbesartan

14.12.2018

Swissmedic laboratory publishes test method for nitrosamines in sartans

Test method for active substances and finished medicinal products

13.12.2018

ICH Meeting in Charlotte, USA, 10–15 November 2018

Continuation of harmonisation efforts in an increasingly global International Council for Harmonisation

04.12.2018

Reclassification of medicinal products from dispensing category D to E: evaluation concluded

More medicines available for sale over the counter – Patient safety paramount

29.11.2018

Verkaufsabgabe 2018 – Selbstdeklaration

Eingabefrist: 25. Januar 2019

23.11.2018

Analysis of the valsartan batches recalled in July 2018 confirms NDMA contamination

Presence of impurities in recalled valsartan products now proven

16.11.2018

Reclassification of therapeutic products in dispensing category C: Evaluation concluded

The prevailing supply category C will be eliminated.

14.11.2018

Renewed discovery of impurities in valsartan-containing medicines

Swissmedic laboratory discovers contamination with N-nitrosodiethylamine above the tolerated level in certain valsartan batches

06.11.2018

Swissmedic Vigilance News Edition 21

Keywords in this edition: Isotretinoin, DOAC, confusions amphotericin B formulations, guest articles RPVC, transfusion practice, statistical review 2017

05.11.2018

Valsartan: Proprietary medicines on the Swiss market containing sartans are safe in respect of NDMA

Analytical results to date for the proprietary medicinal products containing the active substances valsartan, losartan, olmesartan, candesartan and irbesartan

Last modification 16.11.2017

Top of page